Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
PRINCETON, N.J., Sept. 28, 2017 -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract based on the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch (AG200-15) has been selected for a poster presentation during the North American Forum on Family Planning Annual Meeting being held October 14th – 16th, 2017 in Atlanta, GA. The abstract, titled “Bleeding And Spotting Results From The SECURE Trial: A Phase 3 Study Of The AG200-15 Investigational Transdermal Contraceptive Patch,” will be available in the October 2017 issue of Contraception or online at http://www.contraceptionjournal.org.
The SECURE trial evaluated the clinical safety and efficacy of the investigational transdermal contraceptive patch AG200-15, known as Twirla®, in a diverse, real-world population of women reflective of current weight trends in the United States. The poster will focus on details of the AG200-15 bleeding profile that have not been previously reported.
About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.
Contact:
Mary Coleman
Agile Therapeutics, Inc.
609-356-1921
